Ty -jour t1-经过修订的广泛抗药性结核病的定义的影响 - 欧洲呼吸杂志Au -Guglielmetti，Lorenzo au -Maitre，Thomas au -Fournier le Ray，Laure Au -Sougakoff -Sougakoff，Wladimir au -Robert，JérômeA2-，Y1- 2021/01-2021/01/01/early/2021/04/08/13993003.00641-2021.Abstract N2-最近，世界卫生组织（WHO）发布了对广泛耐药性结核病（XDR-TB）的修订定义，该定义应用于临床和监视的目的从2021年1月1日开始[1，2]。XDR-TB TB的先前定义是TB，对任何氟喹诺酮（左氧氟沙星和/或Moxifloxacin）具有抗性，除了多龙耐药外，除了多龙抗性外，还至少有三种可注射药物（SLI，Capreomycin，kanamycin和amikikacin）中的至少一种。修订后的定义是：结核分枝杆菌引起的结核病菌株，该菌株满足了MDR/RR-TB的定义，并且对任何氟喹诺酮类酮也具有耐药性和至少另一种A组A药物。A当前包括氟喹诺酮类药物（左氧氟沙星或Moxifloxacin），LineZolid和Bedaquiline。此外，XDR-TB现在是WHO的定义，被识别为具有任何氟喹诺酮抗性的MDR/RR-TB。尽管事实证明，先前对XDR-TB的定义可以预测治疗结果不良[3]，但2020年更新似乎与治疗方案的最新变化相符，即较少使用SLI来使用SLI来支持有效的口服药物Bedaquiline和linezolid。此外，大型荟萃分析未能显示出降低死亡率与使用SLI之间的关联，而这种关联显示了Bedaquiline和lineZolid [4]。 In this study, we aimed to measure retrospectively the impact of the revised definition on the epidemiology of XDR-TB in France.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: That the national reference centre receives an annual grant from SantéPublique France; that the laboratory in which they work has received a research grant from Janssen for a study on bedaquiline. ER -